Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, announced a new collaboration with the...
Bristol Myers Squibb announced the first disclosure of primary analysis results from the high-risk, second-line cohort of TRANSCEND FL, an open-label, global, multicenter, Phase...